Skip to Content

GlyBURIDE

Medically reviewed on March 25, 2018

Pronunciation

(GLYE byoor ide)

Index Terms

  • Diabeta
  • Glibenclamide
  • Glybenclamide
  • Glybenzcyclamide
  • Micronase

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Diabeta: 1.25 mg [DSC], 2.5 mg [DSC], 5 mg [DSC] [scored]

Glynase: 1.5 mg, 3 mg, 6 mg [scored]

Generic: 1.25 mg, 1.5 mg, 2.5 mg, 3 mg, 5 mg, 6 mg

Brand Names: U.S.

  • Diabeta [DSC]
  • Glynase

Pharmacologic Category

  • Antidiabetic Agent, Sulfonylurea

Pharmacology

Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites

Absorption

Significant within 1 hour

Metabolism

Hepatic; forms metabolites (weakly active)

Excretion

Feces (50%) and urine (50%) as metabolites

Onset of Action

Serum insulin levels begin to increase 15-60 minutes after a single dose

Time to Peak

Serum: Adults: 2-4 hours

Duration of Action

≤24 hours

Half-Life Elimination

Diaβeta: 10 hours; Glynase PresTab: ~4 hours; may be prolonged with renal or hepatic impairment

Protein Binding

Plasma: Extensive, primarily to albumin

Use: Labeled Indications

Diabetes mellitus, type 2: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Off Label Uses

Gestational diabetes mellitus

A systematic review and meta-analysis of randomized trials comparing glyburide to insulin and/or metformin in gestational diabetes mellitus (GDM) found that women who were treated with glyburide had a higher risk of macrosomia, higher mean infant birth weight, and a higher rate of neonatal hypoglycemia as compared to insulin therapy. Additionally, the same meta-analysis found that women who were treated with glyburide had greater weight gain, higher infant birth weight, and higher rates of macrosomia when compared to those who were treated with metformin. The authors recommended against the use of glyburide in the treatment of women with GDM if insulin or metformin is available [Balsells, 2015]. However, the use of glyburide for GDM has increased over the last decade from 7.4% in 2000 to 64.5% in 2011, surpassing insulin as the most common pharmacotherapy in this condition according to a large, retrospective cohort study based on insurance claims data [Camelo Castillo 2014]. Clinical experience suggests that the use of glyburide may be considered in a select group of patients (eg, younger maternal age, singleton pregnancy, gestational age at time of treatment ≥25 weeks) [Kelley 2015]. Additional trials may be necessary to further define the role of glyburide in GDM.

Based on the American Diabetic Association (ADA) guidelines for the Standards of Medical Care in Diabetes, glyburide may be considered an option in the treatment of gestational diabetes mellitus based on short term safety and efficacy studies. However, because long term safety data is not available, insulin is the preferred treatment when pharmacologic therapy is needed.

Contraindications

Hypersensitivity to glyburide or any component of the formulation; type 1 diabetes mellitus or diabetic ketoacidosis, with or without coma; concomitant use with bosentan.

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to any sulfonylurea or sulfonamide; diabetic precoma or coma, stress conditions (eg, severe infections, trauma, surgery); liver disease or frank jaundice; renal impairment; pregnancy; breastfeeding.

Documentation of allergenic cross-reactivity for sulfonylureas is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Dosing: Adult

Micronized glyburide tablets are not bioequivalent to conventional glyburide tablets; retitration should occur if patients are being transferred to a different glyburide formulation (eg, micronized-to-conventional or vice versa) or from other hypoglycemic agents. When converting to glyburide from other oral hypoglycemic agents with a long half-life (eg, chlorpropamide), observe patient carefully for 2 weeks due to overlapping hypoglycemic effects.

Diabetes mellitus, type 2: Oral:

Conventional tablets (Diaβeta):

Initial: 2.5 to 5 mg daily, administered with breakfast or the first main meal of the day. In patients who are more sensitive to hypoglycemic drugs, start at 1.25 mg daily.

Adjustment: Increase in increments of no more than 2.5 mg daily at weekly intervals based on the patient's blood glucose response

Maintenance: 1.25 to 20 mg daily given as single or divided doses. Some patients (especially those receiving >10 mg daily) may have a more satisfactory response with twice-daily dosing. Maximum: 20 mg daily

Micronized tablets (Glynase PresTab):

Initial: 1.5 to 3 mg daily, administered with breakfast or the first main meal of the day. In patients who are more sensitive to hypoglycemic drugs, start at 0.75 mg daily. Increase in increments of no more than 1.5 mg daily in weekly intervals based on the patient's blood glucose response.

Maintenance: 0.75 to 12 mg daily given as a single dose or in divided doses. Some patients (especially those receiving >6 mg daily) may have a more satisfactory response with twice-daily dosing. Maximum: 12 mg daily

Management of noninsulin-dependent diabetes mellitus in patients previously maintained on insulin: Oral: Initial dosage dependent upon current insulin dosage, see table.

Dose Conversion: Insulin to Glyburide

Current Daily Insulin Dosage

(units daily)

Initial Glyburide Dosage

Conventional Formulation

(mg daily)

Initial Glyburide Dosage

Micronized Formulation

(mg daily)

Insulin Dosage Change

(after glyburide started)

<20

2.5-5

1.5-3

Discontinue

20-40

5

3

Discontinue

>40

5

(increase in increments of 1.25-2.5 mg every 2-10 days)

3

(increase in increments of 0.75-1.5 mg every 2-10 days)

Reduce insulin dosage by 50% (gradually taper off insulin as glyburide dosage increased)

Table has been converted to the following text.

Dose Conversion: Insulin to Glyburide

Current insulin dose: <20 units daily

• Initial daily glyburide dose: 2.5-5 mg (conventional formulation) OR 1.5-3 mg (micronized formulation)

• Discontinue insulin after glyburide is started.

Current insulin dose: 20-40 units daily

• Initial daily glyburide dose: 5 mg (conventional formulation) OR 3 mg (micronized formulation).

• Discontinue insulin after glyburide is started.

Current insulin dose: >40 units daily

• Initial daily glyburide dose: 5 mg (conventional formulation) and increase in increments of 1.25-2.5 mg every 2-10 days OR 3 mg (micronized formulation) and increase in increments of 0.75-1.5 mg every 2-10 days.

• Reduce insulin dosage by 50%; gradually taper off insulin as glyburide dosage is increased.

Dosing: Geriatric

Avoid use (Beers Criteria [AGS 2015]).

Manufacturer’s recommendations:

Conventional tablets (Diaβeta): Oral: Initial: 1.25 mg daily. Conservative initial and maintenance doses are recommended to avoid hypoglycemic reactions.

Micronized tablets (Glynase PresTab): Initial: 0.75 mg daily. Conservative initial and maintenance doses are recommended to avoid hypoglycemic reactions.

Dosing: Renal Impairment

There are no specific dosage adjustments provided in the manufacturer's labeling; however, glyburide is generally not recommended in chronic kidney disease; if sulfonylurea therapy is needed, other agents are preferred (ADA [Tuttle 2014]; Alsahli 2015; KDOQI [Nelson 2012]).

Dosing: Hepatic Impairment

There are no dosage adjustments provided in the manufacturer's labeling; however, use conservative initial and maintenance doses.

Administration

Administer with meals at the same time each day (twice-daily dosing may be beneficial if conventional glyburide doses are >10 mg or micronized glyburide doses are >6 mg). Patients that are NPO or require decreased caloric intake may need doses held to avoid hypoglycemia.

Dietary Considerations

Should be taken with meals at the same time each day (twice-daily dosing may be beneficial if conventional glyburide doses are >10 mg or micronized glyburide doses are >6 mg). Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.

Storage

Conventional tablets (Diaβeta): Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).

Micronized tablets (Glynase PresTab): Store at 20°C to 25°C (68°F to 77°F).

Drug Interactions

Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. Monitor therapy

Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur. Monitor therapy

Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents. Monitor therapy

Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). Avoid combination

Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). Monitor therapy

Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol. Monitor therapy

Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Monitor therapy

Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents. Exceptions: Levobunolol; Metipranolol. Monitor therapy

Bosentan: GlyBURIDE may enhance the hepatotoxic effect of Bosentan. GlyBURIDE may decrease the serum concentration of Bosentan. Bosentan may decrease the serum concentration of GlyBURIDE. Avoid combination

Carbocisteine: Sulfonylureas may enhance the adverse/toxic effect of Carbocisteine. Specifically, sulfonylureas may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. Monitor therapy

Ceritinib: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Concurrent use of ceritinib with a CYP2C9 substrate that has a narrow therapeutic index (eg, warfarin, phenytoin) should be avoided when possible. Monitor therapy

Chloramphenicol (Systemic): May decrease the metabolism of Sulfonylureas. Monitor therapy

Cimetidine: May increase the serum concentration of Sulfonylureas. Monitor therapy

Clarithromycin: May increase the serum concentration of GlyBURIDE. Monitor therapy

Colesevelam: May decrease the serum concentration of GlyBURIDE. Management: Administer glyburide at least 4 hours prior to colesevelam. Consider therapy modification

Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas. Monitor therapy

CycloSPORINE (Systemic): May diminish the therapeutic effect of GlyBURIDE. GlyBURIDE may increase the serum concentration of CycloSPORINE (Systemic). Monitor therapy

Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible. If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects). Consider therapy modification

Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides. Monitor therapy

Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia. Consider therapy modification

Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring. Consider therapy modification

Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas. Monitor therapy

Fluconazole: May increase the serum concentration of Sulfonylureas. Management: Seek alternatives when possible. If used together, monitor closely for increased effects of sulfonylureas if fluconazole is initiated/dose increased, or decreased effects if fluconazole is discontinued/dose decreased. Consider therapy modification

Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving both basal insulin and a sulfonylurea. Consider therapy modification

Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents. Monitor therapy

Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Monitor therapy

Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents. Monitor therapy

Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents. Monitor therapy

Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Monitor therapy

Letermovir: May increase the serum concentration of GlyBURIDE. Monitor therapy

Lumacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Monitor therapy

Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. Avoid combination

Metreleptin: May enhance the hypoglycemic effect of Sulfonylureas. Management: Sulfonylurea dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin. Monitor closely. Consider therapy modification

Miconazole (Oral): May enhance the hypoglycemic effect of Sulfonylureas. Miconazole (Oral) may increase the serum concentration of Sulfonylureas. Monitor therapy

MiFEPRIStone: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment. Consider therapy modification

Mitiglinide: May enhance the adverse/toxic effect of Sulfonylureas. Avoid combination

Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy

Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy

Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. Monitor therapy

Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas. Monitor therapy

Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy

Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. Monitor therapy

RaNITIdine: May increase the serum concentration of Sulfonylureas. Monitor therapy

RifAMPin: May decrease the serum concentration of Sulfonylureas. Management: Seek alternatives to these combinations when possible. Monitor closely for diminished therapeutic effects of sulfonylureas if rifampin is initiated/dose increased, or enhanced effects if rifampin is discontinued/dose decreased. Consider therapy modification

Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Monitor therapy

Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents. Monitor therapy

Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy

Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy

Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia. Consider therapy modification

SORAfenib: May enhance the hypoglycemic effect of GlyBURIDE. Monitor therapy

Sulfonamide Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. Monitor therapy

Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents. Monitor therapy

Thiazolidinediones: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose adjustments in patients taking thiazolidinediones and monitor for hypoglycemia. Consider therapy modification

Tolvaptan: May increase the serum concentration of GlyBURIDE. Consider therapy modification

Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. Monitor therapy

Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas. Monitor therapy

Voriconazole: May increase the serum concentration of Sulfonylureas. Monitor therapy

Adverse Reactions

1% to 10%:

Gastrointestinal: Epigastric fullness (≤2%), heartburn (≤2%), nausea (≤2%)

Hypersensitivity: Hypersensitivity reaction (2%; including erythema, maculopapular rash, morbilliform rash, pruritus, urticaria)

Frequency not defined:

Central nervous system: Disulfiram-like reaction

Endocrine & metabolic: Hypoglycemia, hyponatremia, weight gain

Genitourinary: Diuresis (minor)

Hematologic & oncologic: Hemolytic anemia

Hepatic: Cholestatic jaundice, hepatic failure, hepatitis

<1%, postmarketing, and/or case reports: Accommodation disturbance, angioedema, arthralgia, blurred vision, bullous rash, erythema multiforme, exfoliative dermatitis, increased serum transaminases, myalgia, vasculitis

Warnings/Precautions

Concerns related to adverse reactions:

• Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS) have not supported an association.

• Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished or debilitated patients, and in patients with severe renal and hepatic impairment, adrenal and/or pituitary insufficiency; use with caution.

• Sulfonamide (“sulfa”) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO2NH2). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.

Disease-related concerns:

• Glucose-6-phosphate dehydrogenase deficiency: Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.

• Renal impairment: The metabolism and excretion of glyburide may be slowed in patients with renal impairment and its active metabolites may accumulate in advanced renal insufficiency (Snyder 2004). If hypoglycemia should occur, it may be prolonged. Use of glyburide is generally not recommended in chronic kidney disease (ADA [Tuttle 2014]; Alsahli 2015; KDOQI [Nelson 2012]).

• Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).

Special populations:

• Elderly: Glyburide is a longer-duration sulfonylurea; avoid use in older adults due to potential for severe hypoglycemia (Beers Criteria [AGS 2015]). If sulfonylureas are used, those of shorter duration (eg, glipizide) are preferred (ADA 2018b).

Dosage form specific issues:

• Glyburide tablet formulations: Micronized glyburide tablets are not bioequivalent to conventional glyburide tablets; retitration should occur if patients are being transferred to a different glyburide formulation (eg, micronized-to-conventional or vice versa) or from other hypoglycemic agents.

Other warnings/precautions:

• Appropriate use: Not for use in patients with diabetic ketoacidosis (DKA) or patients with type 1 diabetes mellitus.

• Secondary failure: Loss of efficacy may be observed following prolonged use as a result of the progression of type 2 diabetes mellitus which results in continued beta cell destruction. In patients who were previously responding to sulfonylurea therapy, consider additional factors which may be contributing to decreased efficacy (eg, inappropriate dose, nonadherence to diet and exercise regimen). If no contributing factors can be identified, consider discontinuing use of the sulfonylurea due to secondary failure of treatment. Additional antidiabetic therapy (eg, insulin) will be required.

Monitoring Parameters

Signs and symptoms of hypoglycemia, urine glucose test, fasting blood glucose, hemoglobin A1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2018a])

Pregnancy Considerations

Glyburide crosses the placenta. Some pharmacokinetic properties of glyburide may change during pregnancy (Hebert 2009).

Severe hypoglycemia lasting 4 to 10 days has been noted in infants born to mothers taking a sulfonylurea at the time of delivery. Additional adverse maternal and fetal events have been noted in some studies and may be influenced by maternal glycemic control and/or differences in study design (Bertini 2005; Ekpebegh 2007; Joy 2012; Langer 2000; Langer 2005).

In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018c; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA1c should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2018c; Blumer 2013).

Agents other than glyburide are currently recommended to treat diabetes in pregnant women (ADA 2018c). According to the manufacturer, if glyburide is used during pregnancy, it should be discontinued at least 2 weeks before the expected delivery date.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience nausea, heartburn, weight gain, or bloating. Have patient report immediately to prescriber signs of liver problems (dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or jaundice), signs of low sodium (headache, difficulty focusing, memory impairment, confusion, weakness, seizures, or change in balance), signs of low blood sugar (dizziness, headache, fatigue, feeling weak, shaking, tachycardia, confusion, increased hunger, or sweating), signs of infection, severe loss of strength and energy, vision changes, muscle pain, joint pain, bruising, or bleeding (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide